Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rivaroxaban

FDA-approved product (tablet, oral), marketed as Rivaroxaban, Xarelto.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Rivaroxaban
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute coronary syndrome
  • Atrial fibrillation
  • Coronary artery disease
  • Deep vein thrombosis
  • Peripheral arterial disease
  • Pulmonary embolism
  • Recurrent thrombophlebitis
  • Stroke
  • Thrombotic disease
  • Total joint arthroplasty
  • Venous thromboembolism
  • Venous thrombosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Direct factor xa inhibitors
FDA pharmacologic class
Factor Xa Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Rivaroxaban in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rivaroxaban with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Stepwise vs Standard Anticoagulation for AF Patients Undergoing CIED Implantation (STEP-AF)

    NCT07616414 · start 2026-05-26

    Registered record
    Registry ID
    NCT07616414
    Conditions
    Non-valvular Atrial Fibrillation (NVAF); Thromboembolism; Cardiac Implantable Electronic Device; Perioperative Bleeding; Hematoma Postoperative
    Interventions
    Stepwise Anticoagulation Regimen; Standard Anticoagulation Regimen
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-05-26
    Completion
    2026-12-31
    Enrolment
    424

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-valvular Atrial Fibrillation (NVAF); Thromboembolism; Cardiac Implantable Electronic Device; Perioperative Bleeding +1 more
    InterventionStepwise Anticoagulation Regimen; Standard Anticoagulation Regimen
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction

    NCT06961630 · start 2025-10-07

    Registered record
    Registry ID
    NCT06961630
    Conditions
    Myocardial Injury After Noncardiac Surgery
    Interventions
    Rivaroxaban; Atorvastatin
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2025-10-07
    Completion
    2027-03-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Injury After Noncardiac Surgery
    InterventionRivaroxaban; Atorvastatin
    PhaseEarly phase 1
    Registry statusRecruiting

  • Treatment Outcomes of Direct Oral Anticoagulants in Cerebral Venous Thrombosis in Vietnam

    NCT07083609 · start 2025-07-11

    Registered record
    Registry ID
    NCT07083609
    Conditions
    Cerebral Venous Thrombosis
    Interventions
    Dabigatran; Rivaroxaban
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-07-11
    Completion
    2027-12
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCerebral Venous Thrombosis
    InterventionDabigatran; Rivaroxaban
    PhaseNot recorded
    Registry statusRecruiting

  • Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure

    NCT06957366 · start 2025-04-01

    Registered record
    Registry ID
    NCT06957366
    Conditions
    Atrial Fibrillation (AF); VTE
    Interventions
    PAUSE Perioperative DOAC Management; ASRA Perioperative DOAC Management
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-04-01
    Completion
    2027-12-31
    Enrolment
    920

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation (AF); VTE
    InterventionPAUSE Perioperative DOAC Management; ASRA Perioperative DOAC Management
    PhaseNot applicable
    Registry statusRecruiting

  • Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin

    NCT06517563 · start 2024-08-14

    Registered record
    Registry ID
    NCT06517563
    Conditions
    Coagulation Disorder
    Interventions
    VMX-C001; Rivaroxaban; UFH; Enoxaparin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-08-14
    Completion
    2026-04-13
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoagulation Disorder
    InterventionVMX-C001; Rivaroxaban; UFH; Enoxaparin
    PhasePhase 1
    Registry statusCompleted

  • Prediction of Systemic Thromboembolism and Bleeding in Atrial Fibrillation Patients With Factor Xa Inhibitor (Apixaban, Rivaroxaban) by Echocardiographic Parameters: Prospective Observational Study (AF-ECHO Study)

    NCT06779695 · start 2024-04-21

    Registered record
    Registry ID
    NCT06779695
    Conditions
    Atrial Fibrillation (AF)
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2024-04-21
    Completion
    2031-12-31
    Enrolment
    2,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation (AF)
    InterventionNot recorded
    PhaseNot recorded
    Registry statusActive not recruiting

  • Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus

    NCT06013020 · start 2024-04-01

    Registered record
    Registry ID
    NCT06013020
    Conditions
    STEMI - ST Elevation Myocardial Infarction
    Interventions
    NOAC+DAPT; DAPT
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-04-01
    Completion
    2027-12-31
    Enrolment
    374

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSTEMI - ST Elevation Myocardial Infarction
    InterventionNOAC+DAPT; DAPT
    PhasePhase 4
    Registry statusRecruiting

  • NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI

    NCT05638867 · start 2023-11-25

    Registered record
    Registry ID
    NCT05638867
    Conditions
    Coronary Artery Disease; Percutaneous Coronary Intervention; Acute Coronary Syndrome
    Interventions
    Aspirin + Clopidogrel + Rivaroxaban; Aspirin + Clopidogrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-11-25
    Completion
    2027-01
    Enrolment
    3,944

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Percutaneous Coronary Intervention; Acute Coronary Syndrome
    InterventionAspirin + Clopidogrel + Rivaroxaban; Aspirin + Clopidogrel
    PhasePhase 4
    Registry statusRecruiting

  • The PEERLESS II Study

    NCT06055920 · start 2023-11-17

    Registered record
    Registry ID
    NCT06055920
    Conditions
    Pulmonary Embolism
    Interventions
    FlowTriever System; Anticoagulation Agents
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2023-11-17
    Completion
    2026-10
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Embolism
    InterventionFlowTriever System; Anticoagulation Agents
    PhaseNot applicable
    Registry statusActive not recruiting

  • LAAO Versus NOAC in Patients with AF and PCI

    NCT05353140 · start 2022-09-01

    Registered record
    Registry ID
    NCT05353140
    Conditions
    Atrial Fibrillation; Percutaneous Coronary Intervention
    Interventions
    The WATCHMAN/WATCHMAN FLX device; Rivaroxaban + Clopidogre; Aspirin + Clopidogrel
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2022-09-01
    Completion
    2029-09-20
    Enrolment
    1,386

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Percutaneous Coronary Intervention
    InterventionThe WATCHMAN/WATCHMAN FLX device; Rivaroxaban + Clopidogre; Aspirin + Clopidogrel
    PhaseNot applicable
    Registry statusRecruiting

  • PAtients With Symptomatic Peripheral Artery Disease on Rivaroxaban-acetylsalicylic Acid Combination Therapy (PRO-PAS)

    NCT06239415 · start 2022-03-31

    Registered record
    Registry ID
    NCT06239415
    Conditions
    Peripheral Atherosclerotic Disease
    Interventions
    observation
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-03-31
    Completion
    2024-03-31
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral Atherosclerotic Disease
    Interventionobservation
    PhaseNot recorded
    Registry statusUnknown

  • Trained Immunity by Dual-pathway Inhibition in Coronary Artery Disease

    NCT05210725 · start 2022-03-01

    Registered record
    Registry ID
    NCT05210725
    Conditions
    Coronary Artery Disease
    Interventions
    Rivaroxaban 2.5 Mg Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-03-01
    Completion
    2022-07-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionRivaroxaban 2.5 Mg Oral Tablet
    PhasePhase 4
    Registry statusUnknown

  • CHIPs-VTE Study in Hospitalized Patients With Lung Cancer

    NCT04158973 · start 2021-12-01

    Registered record
    Registry ID
    NCT04158973
    Conditions
    Venous Thromboembolic Disease; Pulmonary Embolism; Deep Venous Thrombosis
    Interventions
    Bleeding-risk based prophylaxis strategy during hospitalization and extended pharmacological treatment after discharge; Routine VTE prophylaxis in hospital
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-12-01
    Completion
    2022-12-31
    Enrolment
    3,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thromboembolic Disease; Pulmonary Embolism; Deep Venous Thrombosis
    InterventionBleeding-risk based prophylaxis strategy during hospitalization and extended pharmacological treatment after discharge; Routine VTE prophylaxis in hospital
    PhaseNot applicable
    Registry statusUnknown

  • Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome

    NCT04794569 · start 2021-11-15

    Registered record
    Registry ID
    NCT04794569
    Conditions
    Deep Vein Thrombosis; Post Thrombotic Syndrome
    Interventions
    tinzaparin; Rivaroxaban
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2021-11-15
    Completion
    2024-01-19
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDeep Vein Thrombosis; Post Thrombotic Syndrome
    Interventiontinzaparin; Rivaroxaban
    PhasePhase 4
    Registry statusTerminated

  • Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery Ectasia

    NCT05233124 · start 2021-09-01

    Registered record
    Registry ID
    NCT05233124
    Conditions
    Acute Coronary Syndrome; Coronary Artery Ectasia
    Interventions
    Rivaroxaban 15 MG; Acetylsalicylic acid 100mg; Clopidogrel 75 Mg Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-09-01
    Completion
    2024-07-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome; Coronary Artery Ectasia
    InterventionRivaroxaban 15 MG; Acetylsalicylic acid 100mg; Clopidogrel 75 Mg Oral Tablet
    PhasePhase 2
    Registry statusUnknown